Related references
Note: Only part of the references are listed.Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
Kimberly C. Claeys et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections
Sylvain Goutelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
Emanuele Durante-Mangoni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
The prevention and management of infections due to multidrug resistant organisms in haematology patients
Jason A. Trubiano et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey
E. M. Trecarichi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial
Fekade Bruck Sime et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
An 8-year survey of strains identified in blood cultures in a clinical haematology unit
A. Bousquet et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Use of Daptomycin to Treat Infections With Methicillin-Resistant Staphylococcus aureus Isolates Having Vancomycin Minimum Inhibitory Concentrations of 1.5 to 2 μg/mL
Patrick M. McDaneld et al.
ANNALS OF PHARMACOTHERAPY (2013)
Considerations for Higher Doses of Daptomycin in Critically Ill Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2013)
The Clinical Relevance of Plasma Protein Binding Changes
Jason A. Roberts et al.
CLINICAL PHARMACOKINETICS (2013)
Clinical characteristics and prognostic significance of serum albumin changes in an internal medicine ward
Dana Barchel et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2013)
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections
Antonello Di Paolo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
GFR Estimation Using the Cockcroft-Gault, MDRD Study, and CKD-EPI Equations in the Elderly
Martin Flamant et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R
Michael N. Neely et al.
THERAPEUTIC DRUG MONITORING (2012)
The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients
Marta Ulldemolins et al.
CLINICAL PHARMACOKINETICS (2011)
Vancomycin susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia isolates in an Italian hospital
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study
Ravina Kullar et al.
PHARMACOTHERAPY (2011)
Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis
Sujata M. Bhavnani et al.
CLINICAL INFECTIOUS DISEASES (2010)
Augmented renal clearance in the Intensive Care Unit: an illustrative case series
Andrew A. Udy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution
Chiara Cattaneo et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2010)
Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies
F. Lamoth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever
Joseph S. Bubalo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Safety of High-Dose Intravenous Daptomycin Treatment: Three-Year Cumulative Experience in a Clinical Program
D. A. Figueroa et al.
CLINICAL INFECTIOUS DISEASES (2009)
Prevalence and significance of hypoalbuminemia in an internal medicine department
Filippo Numeroso et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2008)
Bloodstream infections in cancer patients with febrile neutropenia
Ronald Feld
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2008)
Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma
Jens Martens-Lobenhoffer et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
Mark Benvenuto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients
KVI Rolston et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2006)
Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies
DS Buelga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure
F Pea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia
KVI Rolston
CLINICAL INFECTIOUS DISEASES (2005)
Antimicrobial therapy in critically ill patients - A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability
F Pea et al.
CLINICAL PHARMACOKINETICS (2005)
Population pharmacokineties of daptomycin
B Dvorchik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Teicoplanin in patients with acute leukaemia and febrile neutropenia - A special population benefiting from higher dosages
F Pea et al.
CLINICAL PHARMACOKINETICS (2004)
Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States
H Wisplinghoff et al.
CLINICAL INFECTIOUS DISEASES (2003)
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
BH Dvorchik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
